#China #Suzhou #Dyslipidemia #Ribo Life Science #SR122

Ribo's New Clinical Trial Application in Europe

Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals AB, collectively known as Ribo, have announced the submission of a clinical trial application (CTA) for SR122 in the European Union. SR122 is an innovative dual-targeting siRNA therapeutic designed to address mixed and severe dyslipidemia, including conditions like severe hypertriglyceridemia (sHTG) and mixed dyslipidemia. This move is a significant step in consolidating Ribo's presence in the lipid metabolism disorders sector.

Understanding Dyslipidemia

Dyslipidemia represents a crucial global health challenge, playing a vital role as a major contributor to cardiovascular diseases, which rank as the leading cause of death worldwide. Individuals suffering from mixed dyslipidemia continue to face significant residual cardiovascular risks even with existing lipid-lowering therapies. Moreover, those with severe hypertriglyceridemia are at an elevated risk for acute pancreatitis, indicating a critical need for more effective treatments in this area.

The Unique Approach of SR122

SR122 uniquely targets ApoC3 and PCSK9, two clinically validated pathways that play complementary roles in lipid metabolism. By simultaneously influencing triglyceride-rich lipoproteins and low-density lipoprotein cholesterol (LDL-C), SR122 aims to offer a differentiated treatment approach that could lead to lasting improvements across multiple lipid parameters and associated cardiometabolic risk factors. This targeted dual-action therapy presents a promising avenue for managing lipid levels more comprehensively.

Clinical Phase 1 Study Details

The Phase 1 clinical study of SR122 will be a randomized, placebo-controlled trial focusing on evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered SR122 in healthy participants. This study will mark the first clinical assessment of SR122’s dual mechanism in humans, providing crucial data to support continued development.

Dr. Anders Gabrielsen, Chief Medical Officer at Ribo, underscores the significance of inhibiting both ApoC3 and PCSK9, citing the potential for impressive synergies in reducing lipid-related risks associated with severe hypertriglyceridemia. According to Gabrielsen, the outcomes of this Phase 1 study will serve as a cornerstone for future clinical developments in the intended target population.

Moving Forward

As Ribo advances its clinical Phase 2 studies for RBD5044—its primary lipid product, which is acknowledged as the second most advanced ApoC3-targeted siRNA globally in both Europe and China—this clinical trial application is pivotal. It not only enhances Ribo's lipid pipeline strategy but also solidifies its leadership position in the lipid metabolism disorders niche.

In summary, the submission of the clinical trial application for SR122 reflects Ribo's commitment to innovating in the treatment of dyslipidemia and tackling the pressing global health crisis associated with lipid disorders. The outcomes from this trial will be keenly anticipated, with hopes for substantial advancements in patient care and management of cardiovascular risks.